studies

la/mBC - HR-positive - 1st line (L1), ipatasertib plus paclitaxel vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias progression or deaths (PFS)detailed resultsIPATunity130, 2022 1.00 [0.71; 1.40] 1.00[0.71; 1.40]IPATunity130, 202210%222NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-10-31 23:54 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 352,354 - treatments: 1261